1. Differences between pathologic and non-pathologic high myopia in 4-year outcomes of anti-VEGF therapy for macular neovascularization
- Author
-
Yuki Honda, Manabu Miyata, Masahiro Miyake, Masayuki Hata, Shogo Numa, Yuki Mori, Sotaro Ooto, Hiroshi Tamura, Naoko Ueda-Arakawa, Yuki Muraoka, Ayako Takahashi, Keina Sado, Ai Kido, and Akitaka Tsujikawa
- Subjects
Aflibercept ,Chorioretinal atrophy ,Macular neovascularization ,META-PM study ,Pathologic myopia ,Ranibizumab ,Medicine ,Science - Abstract
Abstract This retrospective observational study aimed to investigate the difference in 4-year outcomes of ranibizumab or aflibercept therapy for macular neovascularization (MNV) with high myopia between pathologic myopia (PM) and non-PM. This study was conducted at Kyoto University Hospital and included consecutive treatment-naïve eyes with active myopic MNV, in which a single intravitreal ranibizumab or aflibercept injection was administered, followed by a pro re nata (PRN) regimen for 4 years. Based on the META-PM study classification, eyes were assigned to the non-PM and PM groups. This study analyzed 118 eyes of 118 patients (non-PM group, 19 eyes; PM group, 99 eyes). Baseline, 1-year, and 2-year best-corrected visual acuity (BCVA) were significantly better in the non-PM group (P = 0.02, 0.01, and 0.02, respectively); however, the 3-year and 4-year BCVA were not. The 4-year BCVA course was similar in both groups. However, the total number of injections over 4 years was significantly higher in the non-PM than in the PM group (4.6 ± 2.6 vs. 2.9 ± 2.6, P = 0.001). Four-year BCVA significantly correlated only with baseline BCVA in both non-PM (P = 0.047, β = 0.46) and PM groups (P
- Published
- 2024
- Full Text
- View/download PDF